J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
On a cross-trial basis varegacestat beats Ogsiveo.
No fewer than four ADCs with this target start human testing.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
